Based on structure–function assays, genetic studies, and small-molecule inhibitor investigations, DOT1L has emerged as a clear therapeutic target in MLL-rearranged AML and clinical trials are currently ongoing (60) as described later in the review. This evidence concerns the gene KMT2A and acute myeloid leukemia.